These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 19884365)

  • 1. Pharmacokinetics and safety of S/GSK1349572, a next-generation HIV integrase inhibitor, in healthy volunteers.
    Min S; Song I; Borland J; Chen S; Lou Y; Fujiwara T; Piscitelli SC
    Antimicrob Agents Chemother; 2010 Jan; 54(1):254-8. PubMed ID: 19884365
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of atazanavir and atazanavir/ritonavir on the pharmacokinetics of the next-generation HIV integrase inhibitor, S/GSK1349572.
    Song I; Borland J; Chen S; Lou Y; Peppercorn A; Wajima T; Min S; Piscitelli SC
    Br J Clin Pharmacol; 2011 Jul; 72(1):103-8. PubMed ID: 21342217
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of lopinavir/ritonavir and darunavir/ritonavir on the HIV integrase inhibitor S/GSK1349572 in healthy participants.
    Song I; Min SS; Borland J; Lou Y; Chen S; Patel P; Ishibashi T; Piscitelli SC
    J Clin Pharmacol; 2011 Feb; 51(2):237-42. PubMed ID: 20489027
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Simplified dolutegravir dosing for children with HIV weighing 20 kg or more: pharmacokinetic and safety substudies of the multicentre, randomised ODYSSEY trial.
    Bollen PDJ; Moore CL; Mujuru HA; Makumbi S; Kekitiinwa AR; Kaudha E; Parker A; Musoro G; Nanduudu A; Lugemwa A; Amuge P; Hakim JG; Rojo P; Giaquinto C; Colbers A; Gibb DM; Ford D; Turkova A; Burger DM;
    Lancet HIV; 2020 Aug; 7(8):e533-e544. PubMed ID: 32763217
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and pharmacokinetics of GSK364735, a human immunodeficiency virus type 1 integrase inhibitor, following single and repeated administration in healthy adult subjects.
    Reddy YS; Min SS; Borland J; Song I; Lin J; Palleja S; Symonds WT
    Antimicrob Agents Chemother; 2007 Dec; 51(12):4284-9. PubMed ID: 17923489
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Pharmacokinetics and safety of dolutegravir in healthy Japanese subjects].
    Wajima T; Koshiba T; Ohno K; Nishimura Y; Kobayashi H; Yoshida N; Nagashima M; Fujiwara T
    Jpn J Antibiot; 2013 Feb; 66(1):1-7. PubMed ID: 23777012
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of enzyme inducers efavirenz and tipranavir/ritonavir on the pharmacokinetics of the HIV integrase inhibitor dolutegravir.
    Song I; Borland J; Chen S; Guta P; Lou Y; Wilfret D; Wajima T; Savina P; Peppercorn A; Castellino S; Wagner D; Hosking L; Mosteller M; Rubio JP; Piscitelli SC
    Eur J Clin Pharmacol; 2014 Oct; 70(10):1173-9. PubMed ID: 25146692
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of carbamazepine on dolutegravir pharmacokinetics and dosing recommendation.
    Song I; Weller S; Patel J; Borland J; Wynne B; Choukour M; Jerva F; Piscitelli S
    Eur J Clin Pharmacol; 2016 Jun; 72(6):665-70. PubMed ID: 26898568
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety, tolerability and pharmacokinetics of doravirine, a novel HIV non-nucleoside reverse transcriptase inhibitor, after single and multiple doses in healthy subjects.
    Anderson MS; Gilmartin J; Cilissen C; De Lepeleire I; Van Bortel L; Dockendorf MF; Tetteh E; Ancona JK; Liu R; Guo Y; Wagner JA; Butterton JR
    Antivir Ther; 2015; 20(4):397-405. PubMed ID: 25470746
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of fosamprenavir-ritonavir on the pharmacokinetics of dolutegravir in healthy subjects.
    Song I; Borland J; Chen S; Peppercorn A; Wajima T; Piscitelli SC
    Antimicrob Agents Chemother; 2014 Nov; 58(11):6696-700. PubMed ID: 25155604
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lack of pharmacokinetic interaction between rilpivirine and integrase inhibitors dolutegravir and GSK1265744.
    Ford SL; Gould E; Chen S; Margolis D; Spreen W; Crauwels H; Piscitelli S
    Antimicrob Agents Chemother; 2013 Nov; 57(11):5472-7. PubMed ID: 23979733
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lack of interaction between the HIV integrase inhibitor S/GSK1349572 and tenofovir in healthy subjects.
    Song I; Min SS; Borland J; Lou Y; Chen S; Ishibashi T; Wajima T; Piscitelli SC
    J Acquir Immune Defic Syndr; 2010 Nov; 55(3):365-7. PubMed ID: 20585260
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study.
    Cahn P; Pozniak AL; Mingrone H; Shuldyakov A; Brites C; Andrade-Villanueva JF; Richmond G; Buendia CB; Fourie J; Ramgopal M; Hagins D; Felizarta F; Madruga J; Reuter T; Newman T; Small CB; Lombaard J; Grinsztejn B; Dorey D; Underwood M; Griffith S; Min S;
    Lancet; 2013 Aug; 382(9893):700-8. PubMed ID: 23830355
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single and multiple dose pharmacokinetics of dolutegravir in the genital tract of HIV-negative women.
    Adams JL; Patterson KB; Prince HM; Sykes C; Greener BN; Dumond JB; Kashuba AD
    Antivir Ther; 2013; 18(8):1005-13. PubMed ID: 23899439
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dolutegravir pharmacokinetics in the genital tract and colorectum of HIV-negative men after single and multiple dosing.
    Greener BN; Patterson KB; Prince HM; Sykes CS; Adams JL; Dumond JB; Shaheen NJ; Madanick RD; Dellon ES; Cohen MS; Kashuba AD
    J Acquir Immune Defic Syndr; 2013 Sep; 64(1):39-44. PubMed ID: 23945251
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Small increase in dolutegravir trough, but equivalent total dolutegravir exposure with simeprevir in HIV/HCV seronegative volunteers.
    MacBrayne CE; Castillo-Mancilla J; Burton JR; MaWhinney S; Wagner CB; Micke K; Fey J; Huntley RT; Larson B; Bushman LR; Kiser JJ
    J Antimicrob Chemother; 2018 Jan; 73(1):156-159. PubMed ID: 29029135
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of dolutegravir in HIV-seronegative subjects with severe renal impairment.
    Weller S; Borland J; Chen S; Johnson M; Savina P; Wynne B; Wajima T; Peppercorn AF; Piscitelli SC
    Eur J Clin Pharmacol; 2014 Jan; 70(1):29-35. PubMed ID: 24096683
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety, Pharmacokinetics and Efficacy of Dolutegravir in Treatment-experienced HIV-1 Infected Adolescents: Forty-eight-week Results from IMPAACT P1093.
    Viani RM; Alvero C; Fenton T; Acosta EP; Hazra R; Townley E; Steimers D; Min S; Wiznia A;
    Pediatr Infect Dis J; 2015 Nov; 34(11):1207-13. PubMed ID: 26244832
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics, Safety and Tolerability of ABT-494, a Novel Selective JAK 1 Inhibitor, in Healthy Volunteers and Subjects with Rheumatoid Arthritis.
    Mohamed MF; Camp HS; Jiang P; Padley RJ; Asatryan A; Othman AA
    Clin Pharmacokinet; 2016 Dec; 55(12):1547-1558. PubMed ID: 27272171
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and short-term safety of 873140, a novel CCR5 antagonist, in healthy adult subjects.
    Adkison KK; Shachoy-Clark A; Fang L; Lou Y; O'Mara K; Berrey MM; Piscitelli SC
    Antimicrob Agents Chemother; 2005 Jul; 49(7):2802-6. PubMed ID: 15980352
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.